Risk factors
Celldex Therapeutics (CLDX) risk factors
Item 1A of every Celldex Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors62 risks3 new4 dropped7 reworded
Operating losses surged to $287.4 million in 2025 with rising clinical and contract manufacturing expenses. New risks highlight FDA shutdowns, NIH indirect cost caps, and intellectual property litigation. Commercial capabilities require expansion ahead of potential product approvals.
Filed Feb 25, 2026 - FY2024 10-K risk factors63 risks
Celldex Therapeutics has no product revenue, relies on outside financing to fund ongoing R&D and clinical trials, and has an accumulated deficit of $1.6 billion as of December 31, 2024.
Filed Feb 27, 2025